Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma

References

• Dang CV, O'Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–264.
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–990.
   PubMed Web of Science ®Google Scholar
• Kalkat M, De Melo J, Hickma KA, et al. MYC deregulation in primary human cancers. Genes. 2017;8(6):151.
   PubMed Web of Science ®Google Scholar
• Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7837–7841.
   PubMed Web of Science ®Google Scholar
• Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21(3):515–523.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–2430.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for research on Cancer; 2017.
   Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–2263.
   PubMed Web of Science ®Google Scholar
• Chong LC, Ben-Neriah S, Slack GW, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2018;2(20):2755–2765.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-Cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368.
   PubMed Web of Science ®Google Scholar
• Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060–2064.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98(10):3082–3086.
   PubMed Web of Science ®Google Scholar
• Affer M, Chesi M, Chen WDG, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28(8):1725–1735.
   PubMed Web of Science ®Google Scholar
• Mikulasova A, Ashby C, Tytarenko RG, et al. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2020;105(4):1055–1066.
   PubMed Web of Science ®Google Scholar
• Jovanović KK, Roche-Lestienne C, Ghobrial IM, et al. Targeting MYC in multiple myeloma. Leukemia. 2018;32(6):1295–1306.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myélome. Blood. 2007;109(8):3489–3495.
   PubMed Web of Science ®Google Scholar
• Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580–5894.
   PubMed Web of Science ®Google Scholar
• Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220–1222.
   PubMed Web of Science ®Google Scholar
• Hutter S, Baer C, Walter W, et al. A novel machine learning based in silico pathogenicity predictor for missense variants in a hematological setting. Blood. 2019;134(Supplement_1):2090–2090.
   Web of Science ®Google Scholar
• Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443.
   PubMed Web of Science ®Google Scholar
• Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–D1067.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Schoch C, Löffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML. J Clin Oncol. 2003;21(2):256–265.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078–3085.
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002;16(1):53–59.
   PubMed Web of Science ®Google Scholar
• McGowan-Jordan J, Simons A, Schmid M. International standing committee on human cytogenomic nomenclature. Basel, New York: Karger; 2016.
   Google Scholar
• Bacher U, Haferlach T, Kern W, et al. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. Cancer Genet Cytogenet. 2010;203(2):169–175.
   PubMedGoogle Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies . Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436(7052):807–811.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Deng Q, Manyam GC, et al. Clinical and biologic significance of MYC genetic mutations in De novo diffuse large B-cell Lymphoma. Clin Cancer Res. 2016;22(14):3593–3605.
   PubMed Web of Science ®Google Scholar
• Hüllein J, Słabicki M, Rosolowski M, et al. MDM4 is targeted by 1q gain and drives disease in burkitt lymphoma. Cancer Res. 2019;79(12):3125–3138.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013; 121(17):3413–3419.
   PubMed Web of Science ®Google Scholar
• Maura F, Rustad EH, Yellapantula V, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia. 2020;34(5):1476–1480.
   PubMed Web of Science ®Google Scholar
• Dib A, Gabrea A, Glebov OK, et al. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr. 2008;2008(39):25–31.
   PubMedGoogle Scholar
• Kim GY, Gabrea A, Demchenko YN, et al. Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets. Genes Chromosomes Cancer. 2014;C(6):467–474.
   Web of Science ®Google Scholar
• Caers J, Garderet L, Kortüm KM, et al. European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103(11):1772–1784.
   PubMed Web of Science ®Google Scholar
• Glitza IC, Lu G, Shah R, et al. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015;56(3):602–607.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014;4(3):e191.
   PubMed Web of Science ®Google Scholar
• Abdallah N, Baughn LB, Rajkumar SV, et al. Implications of MYC rearrangements in newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26(24):6581–6588.
   PubMed Web of Science ®Google Scholar